摘要
目的从胃肠激素的角度研究痛泻要方治疗肠易激综合征的机理。方法32只wistar大鼠随机分成4组:正常对照组,模型对照组、痛泻要方组、得舒特组,后三组大鼠采用束缚应激刺激加灌服番泻叶煎剂的方法造成肠易激综合征(IBS)大鼠模型,观察痛泻要方对肠易激综合征模型大鼠体内胃肠激素血管活性肠肽(VIP)的影响。结果模型对照血浆及局部肠组织中VIP含量与正常对照组比较,均有统计学意义(P<0.05～P<0.01)。痛泻要方组血浆VlP含量与模型对照组比较显著降低,有统计学意义(P<0.01);痛泻要方组局部肠组织中VIP含量与模型对照组比较亦有统计学意义(P<0.05)。结论IBS模型大鼠体内存在VIP水平升高的病理状态,痛泻要方可调控胃肠激素VlP的分泌和释放,进而达到治疗目的。
Objective To explore the mechanism of Tongxieyaofang in the treatment of irritable bowel syndrome from the perspective of gastrointestinal hormone. Methods 32 wistar rats were divided randomly into 4 groups：normal control group,model control group, Tongxieyaofang group and Dicetel group. Using the methods of bindlng,stress and stimulation adding taking senna decoction in the later 3 groups of rats, the rats model of irritable bowel syndrome （IBS） was made. To observe the effects of Tongxieyaofang on gastrointestinal hormones（ vasoactive intestinal polypeptide,VIP） in rats of IBS. Results The contents of VIP iu plasma and intestinal tissue in model group were higher than those in normal group （ P 〈 0.05 - P 〈 0.01 ）. The concentrations of plasma VIP in Tongxieyaofang group decreased more than those in model group（ P 〈0.01 ） , and the contents of VIP in intestinal tissue in Tongxleyaofang group were also lower than those in model group（ P 〈0.05 ）. Conclusion The pathological state of the higher levels of VIP exists in rats model of IBS. Tongxieyaofang can treat IBS probably by adjusting the secretion and release of gastrointestinal hormone （VIP）.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2007年第9期2098-2099,共2页
Lishizhen Medicine and Materia Medica Research
基金
首都医科大学自然科学科研基金(No.2004ZR06)
关键词
痛泻要方
肠易激综合征
大鼠
血管活性肠肽
Tongxieyaofang
lfitable bowel syndrome
Rats
Vasoactive intestinal polypeptide
作者简介
李冬华（1972-），女（汉族），河南扶沟人，现任首都医科大学中医药学院讲师，博士学位，主要从事中医学实验研究工作．
